ReviewMolecular medicine reports2025
Application potential of induced pluripotent stem cells in the research and treatment of autoimmune diseases (Review).
Review in Molecular medicine reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A Review of the Clinical Applicability of Neurotrophins in Cochlear Implantation.Journal of audiology & otology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Autoimmune diseases are a group of disorders caused by the immune system mistakenly attacking the body's own tissues, including type 1 diabetes, rheumatoid arthritis and multiple sclerosis (MS). These diseases are typically accompanied by chronic inflammation and tissue damage, which markedly impact the quality of life of patients. Induced pluripotent stem cells (iPSCs), owing to their unlimited proliferative capacity and pluripotency, demonstrate unique advantages in the field of regenerative medicine. iPSCs can be induced to differentiate into various functional cells in vitro providing potentially important tools for disease modeling, drug screening and cell therapy. For example, iPSCs can be directed to generate cardiomyocytes, dopaminergic neurons, hepatocyte‑like cells and pancreatic β‑cells, highlighting their broad potential for translational applications. For treating autoimmune diseases, iPSCs can be utilized for tissue repair, replacement therapy and the induction of cells with immunoregulatory functions. The present review summarizes the latest advancements in iPSC technology and its research in various autoimmune diseases, including MS, rheumatoid arthritis, systemic lupus erythematosus, type 1 diabetes and systemic sclerosis. The present study also discusses the main challenges in the application of iPSCs, aiming to provide a theoretical basis and practical guidance for developing novel therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.